Drug Profile
MAK 683
Alternative Names: MAK-683Latest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Polycomb repressive complex 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
Most Recent Events
- 03 Jun 2022 Pharmacodynamics and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 18 Feb 2022 Phase-I/II development in Lymphoma (Late-stage disease, Metastatic disease, Recurrent) is ongoing in Canada, China, France, Germany, Hong Kong, Italy, Japan, Singapore, Spain, USA (PO) (NCT02900651) (EudraCT2016-001860-12)
- 18 Feb 2022 Phase-I/II development in Solid tumours (Late-stage disease, Metastatic disease, Recurrent) is ongoing in Canada, China, France, Germany, Hong Kong, Italy, Japan, Singapore, Spain, USA (PO) (NCT02900651) (EudraCT2016-001860-12)